Every 10-Q that Processa Pharmaceuticals, Inc. Common (PCSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals reported a Q2 2026 net loss of $3.27 million and a six‑month net loss of $6.64 million, similar to the prior year. Operating expenses for the quarter were driven by $0.65 million in research and development and $1.69 million in general and administrative costs.
At June 30, 2026, cash and cash equivalents were $196,325, with total assets of $2.07 million and a stockholders’ deficit of $0.32 million. The company used $5.59 million of cash in operating activities in the first half and held Chiliz digital assets with a fair value of $472,003, recognizing $0.99 million in realized and unrealized losses.
Subsequently, on July 28, 2026, Processa acquired Vidya Therapeutics, adding lead BTK inhibitor VT‑7208 for food allergy, CSU and RMS, and closed a related private placement of Series A Preferred Stock for $200 million gross ($183.3 million net). Management states these proceeds are expected to fund operations into the second half of 2029, eliminating the previously disclosed going‑concern uncertainty.
Processa Pharmaceuticals (PCSA) filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Net loss was $3,436,573 for the quarter and $10,204,896 year‑to‑date. Cash and cash equivalents were $6,308,420 as of September 30, 2025. Management says existing cash, plus subsequent warrant proceeds, should fund operations into the first quarter of 2026.
The company raised capital through multiple 2025 transactions, including $4.4 million in January and $6.2 million in June offerings, $1.2 million via an accredited investor sale, and $1.0 million under its ATM, with additional warrant exercises before and after quarter‑end. Processa began implementing a cryptocurrency treasury strategy and held $350,000 in USD‑backed stablecoins at quarter‑end, increasing to $850,000 after. Shares outstanding were 56,644,223 as of November 3, 2025. R&D expense was $1.66 million and G&A was $1.83 million in Q3. The Nasdaq minimum bid price deficiency period was extended through February 2, 2026.
Key results (Q2 2025): Processa reported $6,936,620 cash at June 30, 2025 and a six-month net loss of $6,768,323 (operating loss $6,797,773). The company had an accumulated deficit of $93,987,522 and used $5,000,253 cash in operating activities during the six months ended June 30, 2025.
Financing and liquidity: Net proceeds of $10.6 million were raised from January and June public offerings; all pre-funded warrants from those offerings were exercised. Management states cash plus $2.4 million gross August 2025 proceeds are expected to fund operations into Q1 2026, but substantial doubt exists about going concern beyond one year.
Material developments: Entered a binding term sheet with Intact Therapeutics for PCS12852 that contemplates a $2.5 million license payment (timing specified) and a 3.5% equity interest in Intact plus potential milestones/royalties; contractual CRO commitments total up to $13.1 million. Nasdaq notified the company of noncompliance with the $1.00 minimum bid rule.